NO20065013L - Controlled release dosage for GABA receptor agonist - Google Patents

Controlled release dosage for GABA receptor agonist

Info

Publication number
NO20065013L
NO20065013L NO20065013A NO20065013A NO20065013L NO 20065013 L NO20065013 L NO 20065013L NO 20065013 A NO20065013 A NO 20065013A NO 20065013 A NO20065013 A NO 20065013A NO 20065013 L NO20065013 L NO 20065013L
Authority
NO
Norway
Prior art keywords
receptor agonist
controlled release
release dosage
gaba receptor
release properties
Prior art date
Application number
NO20065013A
Other languages
Norwegian (no)
Inventor
Chien-Hsuan Han
Ann Hsu
Larry Hsu
Charles Hsiao
Ching-Ling Diana Teng
Original Assignee
Impax Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/815,930 external-priority patent/US20050220874A1/en
Priority claimed from US10/815,929 external-priority patent/US20050220864A1/en
Priority claimed from US10/815,924 external-priority patent/US20050220863A1/en
Priority claimed from US10/815,926 external-priority patent/US20050220873A1/en
Application filed by Impax Laboratories Inc filed Critical Impax Laboratories Inc
Publication of NO20065013L publication Critical patent/NO20065013L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Foreliggende oppfinnelse vedrører generelt farmasøytiske doseringsformer som har umiddelbart frigivende egenskaper og kontrollert frigivende egenskaper som inneholder en ?-aminosmørsyre (GABAB)-reseptoragonist, f.eks. baklofen, til behandlingen av medisinske tilstander, som inkluderer spasmer, kramper og muskelhardhet, assosiert med lidelser, slik som multippel sklerose eller visse ryggmargsskader.The present invention generally relates to pharmaceutical dosage forms having immediate release properties and controlled release properties containing a? -Aminobutyric acid (GABAB) receptor agonist, e.g. baclofen, for the treatment of medical conditions, which include spasms, cramps and muscle hardness, associated with disorders such as multiple sclerosis or certain spinal cord injuries.

NO20065013A 2004-04-02 2006-11-01 Controlled release dosage for GABA receptor agonist NO20065013L (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/815,930 US20050220874A1 (en) 2004-04-02 2004-04-02 Pharmaceutical dosage forms having immediate release and controlled release properties that contain a GABAB receptor agonist
US10/815,929 US20050220864A1 (en) 2004-04-02 2004-04-02 Pharmaceutical dosage forms having controlled release properties that contain a GABAB receptor agonist
US10/815,924 US20050220863A1 (en) 2004-04-02 2004-04-02 Pharmaceutical dosage forms having controlled release properties that contain a GABAB receptor agonist
US10/815,926 US20050220873A1 (en) 2004-04-02 2004-04-02 Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
PCT/US2005/011032 WO2005097079A2 (en) 2004-04-02 2005-04-01 Controlled release dosage for gaba receptor agonist

Publications (1)

Publication Number Publication Date
NO20065013L true NO20065013L (en) 2007-01-02

Family

ID=35060819

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065013A NO20065013L (en) 2004-04-02 2006-11-01 Controlled release dosage for GABA receptor agonist

Country Status (11)

Country Link
EP (1) EP1729740A2 (en)
JP (1) JP2007531727A (en)
KR (1) KR20070020022A (en)
AU (1) AU2005231433A1 (en)
BR (1) BRPI0509399A (en)
CA (1) CA2560995A1 (en)
IL (1) IL178296A0 (en)
MX (1) MXPA06011322A (en)
NO (1) NO20065013L (en)
TW (1) TW200536523A (en)
WO (1) WO2005097079A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2117517B1 (en) * 2007-01-11 2011-06-01 XenoPort, Inc. Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment
WO2009096985A1 (en) * 2008-02-01 2009-08-06 Xenoport, Inc. Sustained release particulate oral dosage forms of (r)-baclofen prodrugs and methods of treatment
WO2010102071A1 (en) 2009-03-03 2010-09-10 Xenoport, Inc. Sustained release oral dosage forms of an r-baclofen prodrug
RU2672884C1 (en) * 2017-11-07 2018-11-20 Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский государственный педагогический университет им. А.И. Герцена" (РГПУ им. А.И. Герцена) Agent for preserving population of gaba-ergic neurons after acute perinatal hypoxia
JP7138666B2 (en) * 2018-01-24 2022-09-16 大原薬品工業株式会社 METHOD FOR IMPROVING CHEMICAL STABILITY OF TABLETS CONTAINING γ-AMINOBUTYRIC ACID DERIVATIVES

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9308430D0 (en) * 1993-04-23 1993-06-09 Glaxo Group Ltd Medicaments
CA2430298A1 (en) * 2000-11-30 2002-06-06 Banavara Lakshman Mylari Combination of gaba agonists and sorbitol dehydrogenase inhibitors

Also Published As

Publication number Publication date
BRPI0509399A (en) 2007-09-18
EP1729740A2 (en) 2006-12-13
WO2005097079A3 (en) 2006-01-05
KR20070020022A (en) 2007-02-16
JP2007531727A (en) 2007-11-08
TW200536523A (en) 2005-11-16
IL178296A0 (en) 2007-02-11
MXPA06011322A (en) 2007-02-21
WO2005097079A2 (en) 2005-10-20
CA2560995A1 (en) 2005-10-20
AU2005231433A1 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
WO2006128070A3 (en) Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a gabab receptor agonist
MXPA05011523A (en) Substituted heteroaryls as inhibitors of protein tyrosine phosphatases.
MX2009006339A (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity.
NO20092905L (en) Dosage regimen for COMT inhibitors
NO20065013L (en) Controlled release dosage for GABA receptor agonist
NO20072461L (en) Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity
NO20065984L (en) Compounds and compositions as PPAR modulators
TW200630096A (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2009111700A3 (en) Oxadiazoanthracene compounds for the treatment of diabetes
NO20065983L (en) Compounds and compositions as PPAR modulators
MXPA05011536A (en) Phenyl substituted carboxylic acids.
MXPA03010232A (en) Novel, arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders.
ECSP088852A (en) AZOLOPIRIMIDINS AS INHIBITORS OF CANABINOID ACTIVITY 1
RS20050814A (en) Substituted amino carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
TW200630354A (en) Substituted amino carboxylic acids
MX336318B (en) Co-crystals of tramadol and nsaids.
EA200900749A1 (en) 1,4-DIAMINOBICYCLIC ANALOGUES OF RETIGABIN AS MODULATORS OF POTASSIUM CHANNELS
BR112021019880A2 (en) Gene therapies for lysosomal disorders
EA201001586A1 (en) COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS
NO20062142L (en) Extended release pharmaceutical dosage form
WO2007070840A3 (en) Modified and pulsatile release pharmaceutical formulations of escitalopram
MX2007002583A (en) Methods and compositions for enhancing degradation of nuclear receptor transcription factors and uses thereof.
PA8642901A1 (en) AMIDAS OF ACID 5 AND 6-AMINOALQUIL INDOL-2-CARBOXILICO 3-SUBSTITUTES AND RELATED ANALOGS AS INHIBITORS OF CASEINA CINASA I
WO2007048080A3 (en) Stable pharmaceutical formulations containing escitalopram and bupropion
MX2009011929A (en) Controlled release oral formulations of ion channel modulating compounds and related methods for preventing arrhythmia.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application